Rein Therapeutics Inc.

RNTX Healthcare Biotechnology

In the quarter to June 2026, EPS grew 64.3% and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.59 0.04 −6.35%
Market cap
$54.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(753.55%) 351.84% 533.38% (229.07%)

+8 more TTM periods

ROA
(80.62%) (119.66%) (115.51%) (74.57%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(156.76%) 613.49% 2,689.91% 10,330.70%
Free Cash Flow per Share
(0.28) (0.55) (0.76) (0.79)
Free Cash Flow
(18.83) (16.61) (19.36) (20.95)
Other line items

Show all line items

Columns are period end dates